Study of Telitacicept in Generalized Myasthenia Gravis

Summary

The purpose of this study is to evaluate the efficacy and safety of Telitacicept in the treatment of patients with generalized myasthenia gravis.

Timeline

Start

2023-03-28

Primary completion

2024-11-26

Completion

2024-12-12

Outcome

Met primary endpoint

release “Telitacicept (RC18, trade name: Tai'ai®) in treatment of generalized myasthenia gravis (gMG) had achieved its primary endpoint” remegen.com ↗

Drugs

Indications